Alterity Therapeutics ATH434 Shows Reduced Functional Decline in Multiple System Atrophy Phase 2 Trial

Key Takeaways

• ATH434 reduced functional decline compared to placebo at Week 52 using the MuSyCA composite scale in multiple system atrophy patients
• Positive effects observed in both daily function and neurological examination, consistent with previous modified UMSARS Part I results
• Data strengthens ATH434’s clinical profile as Alterity prepares for Phase 3 regulatory discussions

---

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented encouraging new analysis of its ATH434 Phase 2 trial data at the American Academy of Neurology’s Late Breaking Science Session on April 22, 2026.

The Melbourne and San Francisco-based biotechnology company reported that ATH434 demonstrated a statistically significant reduction in functional decline versus placebo at Week 52 when measured using MuSyCA, a newly described composite scale for multiple system atrophy (MSA).

Clinical Significance and Patient Impact

The positive results span both daily functional activities and neurological examination measures, reinforcing previously reported activity on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I. This consistency across multiple assessment tools strengthens the evidence for ATH434’s therapeutic potential in MSA, a rare and progressive neurodegenerative disorder with limited treatment options.

MSA affects approximately 15,000-50,000 Americans and is characterized by a combination of parkinsonism, cerebellar dysfunction, and autonomic failure. The disease typically progresses rapidly, with patients experiencing significant disability within 5-10 years of symptom onset.

Regulatory Pathway Forward

The new analysis reinforces ATH434’s clinical profile as Alterity prepares for Phase 3 engagement with regulatory authorities. The company’s iron chelation approach targets abnormal iron accumulation in the brain, which is believed to contribute to neurodegeneration in MSA and other movement disorders.

ATH434’s mechanism of action involves selectively reducing iron levels in affected brain regions while maintaining iron availability for essential cellular functions. This targeted approach differentiates it from traditional iron chelators that can cause systemic iron depletion.

Market Implications

The positive Phase 2 results position Alterity favorably in the competitive landscape for MSA treatments. With no FDA-approved therapies specifically indicated for MSA, ATH434 could address a significant unmet medical need if successfully developed through Phase 3 trials.

The presentation at the American Academy of Neurology’s prestigious Late Breaking Science Session underscores the clinical significance of these findings within the neurology community.

---

Frequently Asked Questions

What does this mean for multiple system atrophy patients?

The results suggest ATH434 may slow functional decline in MSA patients, potentially preserving daily living abilities and neurological function longer than current standard care. However, the drug still requires Phase 3 testing before potential FDA approval.

When will ATH434 be available to patients?

ATH434 is still in clinical development. Alterity must complete Phase 3 trials and obtain regulatory approval before the drug becomes commercially available, which typically takes several years from current stage.

How does ATH434 compare to existing MSA treatments?

Currently, there are no FDA-approved treatments specifically for MSA. Existing care focuses on managing symptoms. ATH434’s targeted iron chelation approach represents a novel mechanism that could potentially slow disease progression rather than just treating symptoms.